Mutagenicity of new lead compounds to treat sickle cell disease symptoms in a Salmonella/microsome assay.
A series of phthalimide derivatives planned as drugs candidates to treat the symptoms of sickle cell anemia were evaluated in a mutagenicity test using strains of Salmonella typhimurium TA100 and TA102, without and with addition of S9 mixture, with the aim to identify the best structural requirements for a drug candidate without genotoxic activity. The compounds (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl nitrate (1); (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl nitrate (2); 3-(1,3-dioxo-1,3-dihydro-2H-iso-indol-2-yl)benzyl nitrate (3); 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-hydroxy-benzenesulfonamide (4); 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzyl nitrate (5) and 2-[4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]ethyl nitrate (6) presented mutagenic potency ranging between 0-4,803 revertants/micromol. These results allowed us to propose that a methyl spacer linked to a nitrate ester subunit associated to meta aromatic substitution decreases mutagenicity.
dos Santos
Jean Leandro
JL
Departamento de Fármacos e Medicamentos, Univ Estadual Paulista-UNESP, Araraquara, SP, Brazil. santosjl@fcfar.unesp.br <santosjl@fcfar.unesp.br>
Varanda
Eliana A
EA
Lima
Lídia Moreira
LM
Chin
Chung Man
CM
D000755:Anemia, Sickle Cell / Q000188:drug therapy; D000818:Animals; D006801:Humans; D008862:Microsomes, Liver / Q000187:drug effects* / Q000378:metabolism; D009152:Mutagenicity Tests; D010797:Phthalimides / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012486:Salmonella typhimurium / Q000187:drug effects*; D013329:Structure-Activity Relationship
D010797:Phthalimides; C037431:phthalimide
Cancer Res. 1972 Oct;32(10):2058-66
4404160
Food Chem Toxicol. 2006 Sep;44(9):1585-9
16730111
Mutat Res. 1992 Mar;281(3):193-202
1371842
Toxicol Lett. 1985 Jan;24(1):111-6
3883575
Toxicol In Vitro. 2004 Dec;18(6):895-900
15465657
Teratog Carcinog Mutagen. 2001;21(5):349-59
11746249
Mutat Res. 1977 Sep;56(1):7-12
339075
Can J Genet Cytol. 1979 Sep;21(3):319-34
393369
Mutat Res. 1982 Aug;97(4):267-81
6750390
Chem Res Toxicol. 1993 Nov-Dec;6(6):895-9
8117930
Semin Oncol. 1992 Jun;19(3 Suppl 9):11-9
1641651
Mutat Res. 2008 Jan 8;649(1-2):213-20
17988936
Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):1-8
19275572
Mutat Res. 2003 Aug 5;539(1-2):203-6
12948829
Mutat Res. 1985 Nov-Dec;152(2-3):225-31
4069149
Bioorg Med Chem. 2002 Sep;10(9):3067-73
12110331
Trends Pharmacol Sci. 2006 Apr;27(4):204-10
16530854
ScientificWorldJournal. 2008 Dec 25;8:1295-324
19112541
Chem Biol Interact. 1988;67(3-4):215-23
3056625
Nitric Oxide. 1997 Apr;1(2):158-66
9701054
Mutat Res. 1983 May;113(3-4):173-215
6341825